Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau

Translational Neurodegeneration

Volumn 1, Issue , 2012, Pages

  Hong Qi, Yang ^a   Zhi Kun, Sun ^a   Sheng Di, Chen ^b  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Beta amyloid; Pathogenesis; Tau; Treatment

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; BMS 299897; CEVIMELINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE INHIBITOR; GSK 188909; HOMOTAURINE; HUPERZINE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; LADOSTIGIL; MONOAMINE OXIDASE INHIBITOR; MRK 560; PHENSERINE; PLACEBO; PMS 777; RIVASTIGMINE; SELEGILINE; SEMAGACESTAT; SOLANEZUMAB; TACRINE; TALSACLIDINE; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BRAIN EDEMA; CELL TRANSPLANTATION; CHOLINERGIC SYSTEM; DAILY LIFE ACTIVITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENE THERAPY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNOTHERAPY; LIVER TOXICITY; MENINGOENCEPHALITIS; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PASSIVE IMMUNIZATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SKIN TOXICITY; UNSPECIFIED SIDE EFFECT;

EID: 84879601934     PISSN: None     EISSN: 20479158     Source Type: Journal    
DOI: 10.1186/2047-9158-1-21     Document Type: Review

References (66)

1. Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurol 2011, 11:57. 10.1186/1471-2377-11-57, 3126705, 21612646.
2. Yang HQ, Xing Y. Role of neprilysin in the pathogenesis of Alzheimer's disease. Prog Biochem Biophys 2012, 39(8):721-725.
3. Yang HQ, Sun ZK, Zhao YX, Pan J, Ba MW, Lu GQ, Ding JQ, Chen HZ, Chen SD. PMS777, a new cholineraterase inhibitor with anti-platelet activated factor activity activity, regulates amyloid precursor protein processing in vitro. Neurochem Res 2009, 34(3):528-535. 10.1007/s11064-008-9816-4, 18758955.
4. So PP, Zeldich E, Seyb KI, Huang MM, Concannon JB, King GD, Chen CD, Cuny GD, Glicksman MA, Abraham CR. Lowering of amyloid beta peptide production with a small molecule inhibitor of amyloid-β precursor protein dimerization. Am J Neurodegener Dis 2012, 1(1):75-87. 3401075, 22822474.
5. Wang T, Sun XL. Molecular regulaion of BACE1 and its function at the early onset of Alzheimer's disease. Prog Biochem Biophys 2012, 39(8):709-714.
6. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011, 10(9):698-712. 10.1038/nrd3505, 21852788.
7. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, Fahrenholz F. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer's disease mouse model. J Clin Invest 2004, 113(10):1456-1464. 406531, 15146243.
8. Yang HQ, Ba MW, Ren RJ, Zhang YH, Ma JF, Pan J, Lu GQ, Chen SD. Mitogen activated protein kinase and protein kinase C mediated promotion of sAPPα by deprenyl. Neurochem Int 2007, 50(1):74-82. 10.1016/j.neuint.2006.07.016, 16973242.
9. Yang HQ, Pan J, Ba MW, Sun ZK, Ma GZ, Lu GQ, Xiao Q, Chen SD. New protein kinase C activator regulates amyloid precursor protein processing in vitro by increasing α-secretase activity. Eur J Neurosci 2007, 26(2):381-391. 10.1111/j.1460-9568.2007.05648.x, 17650113.
10. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell. 2010, 142(2):320-332. 10.1016/j.cell.2010.06.020, 2911635, 20655472.
11. Yang HQ, Sun ZK, Ba MW, Xu J, Xing Y. Involvement of protein trafficking in deprenyl-induced α-secretase activity regulation in PC12 cells. Eur J Pharmacol 2009, 610(1~2):37-41.
12. Alagiakrishnan K, Gill SS, Fagarasanu A. Genetics and epigenetics of Alzheimer's disease. Postgrad Med J 2012, 88(1043):522-529. 10.1136/postgradmedj-2011-130363, 22543304.
13. Kozikowski AP, Chen Y, Subhasish T, Lewin NE, Blumberg PM, Zhong Z, D'Annibale MA, Wang WL, Shen Y, Langley B. Searching for disease modifiers-PKC activation and HDAC inhibition - a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress. Chem Med Chem 2009, 4(7):1095-1105. 3057395, 19396896.
14. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61(1):46-54. 10.1212/01.WNL.0000073623.84147.A8, 12847155.
15. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372(9634):216-223. 10.1016/S0140-6736(08)61075-2, 18640458.
16. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E, for the AAB-001 201/202 Investigators Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012, 69(8):1002-1010. 10.1001/archneurol.2012.90, 22473769, for the AAB-001 201/202 Investigators.
17. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9(4):363-372. 10.1016/S1474-4422(10)70043-0, 20189881.
18. Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 2009, 10(1):94-100. 10.1038/embor.2008.222, 2613207, 19057576.
19. Bauer C, Pardossi-Piquard R, Dunys J, Roy M, Checler F. γ-Secretase-Mediated Regulation of Neprilysin: Influence of Cell Density and Aging and Modulation by Imatinib. J Alzheimer's Dis 2011, 27(3):511-520.
20. Nalivaeva NN, Belyaev ND, Lewis DI, Pickles AR, Makova NZ, Bagrova DI, Dubrovskaya NM, Plesneva SA, Zhuravin IA, Turner AJ. Effect of Sodium Valproate Administration on Brain Neprilysin Expression and Memory in Rats. J Mol Neurosci 2012, 46(3):569-577. 10.1007/s12031-011-9644-x, 21932040.
21. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 2010, 330(6012):1774. 10.1126/science.1197623, 3073454, 21148344.
22. Mulder SD, Veerhuis R, Blankenstein MA, Nielsen HM. The effect of amyloid associated proteins on the expression of genes involved in amyloid-β clearance by adult human astrocytes. Exp Neurol 2012, 233(1):373-379. 10.1016/j.expneurol.2011.11.001, 22101005.
23. Jiang Q, Lee CY, Mandrekar S. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58(5):681-693. 10.1016/j.neuron.2008.04.010, 2493297, 18549781.
24. Cramer PE, Cirrito JR, Wesson DW. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science. 2012, 335(6075):1503-1506. 10.1126/science.1217697, 22323736.
25. Strittmatter WJ. Medicine. Old drug, new hope for Alzheimer's disease. Science 2012, 335(6075):1447-1448. 10.1126/science.1220725, 22442467.
26. Yang HQ. Role of apolipoprotein E in Aβ clearance promoting. Prog Biochem Biophys 2012, 39(8):829-830.
27. Weinreb O, Amit T, Bar-Am O, Youdim MB. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets 2012, 13(4):483-494. 10.2174/138945012799499794, 22280345.
28. Bolea I, Juárez-Jiménez J, de Los Ríos C, Chioua M, Pouplana R, Luque FJ, Unzeta M, Marco-Contelles J, Samadi A. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J Med Chem 2011, 54(24):8251-8270. 10.1021/jm200853t, 22023459.
29. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T, Davies P, Burns M, Veeranna, Nixon R, Dickson D, Matsuoka Y, Ahlijanian M, Lau LF, Duff K. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003, 38(4):555-565. 10.1016/S0896-6273(03)00259-9, 12765608.
30. Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006, 314(5800):781-784. 10.1126/science.1132813, 17082448.
31. Yeh HL, Tsai SJ. Lithium may be useful in the prevention of Alzheimer's disease in individuals at risk of presenile familial Alzheimer's disease. Med Hypotheses 2008, 71(6):948-951. 10.1016/j.mehy.2008.03.049, 18760542.
32. Husain MM, Trevino K, Siddique H, McClintock SM. Present and prospective clinical therapeutic regimens for Alzheimer's disease. Neuropsychiatr Dis Treat 2008, 4(4):765-777. 2536544, 19043521.
33. Roder HM, Hutton ML. Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease. Expert Opin Ther Targets 2007, 11(4):435-442. 10.1517/14728222.11.4.435, 17373874.
34. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM, Biernat J, Mandelkow E. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem 2005, 280(5):3628-3635.
35. Ballatorea C, Brundenb KR, Trojanowskib JQ, Lee VMY, Smith AB, Huryn D. Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies. Curr Top Med Che 2011, 11(3):317-330.
36. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H. Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci USA 2003, 100(2):721-726. 10.1073/pnas.242720499, 141063, 12522269.
37. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, Burrows F, Eckman C, Hutton M, Petrucelli L. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. Faseb J 2006, 20(6):753-755.
38. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007, 27(34):9115-9129. 10.1523/JNEUROSCI.2361-07.2007, 17715348.
39. Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010, 30(49):16559-16566. 10.1523/JNEUROSCI.4363-10.2010, 3135981, 21147995.
40. Kayed R. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum Vaccin 2010, 6(11):931-935. 10.4161/hv.6.11.12689, 20980799.
41. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010, 224(2):472-485. 10.1016/j.expneurol.2010.05.010, 20546729.
42. Chohan MO, Iqbal K. From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease. J Alzheimers Dis 2006, 10(1):81-87.
43. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006, 14(8):704-715. 10.1097/01.JGP.0000224350.82719.83, 16861375.
44. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, Goodman SN. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004, 23(4):159-169. 10.1159/000078501, 15279021.
45. Côté S, Carmichael PH, Verreault R, Lindsay J, Lefebvre J, Laurin D. Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimers Dement 2012, 8(3):219-226. 10.1016/j.jalz.2011.03.012, 22546354.
46. Merlo S, Sortino MA. Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation. Mol Cell Neurosci 2012, 49(4):423-429. 10.1016/j.mcn.2012.02.005, 22402435.
47. Henderson VW. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 2006, 138(3):1031-1039. 10.1016/j.neuroscience.2005.06.017, 16310963.
48. Wharton W, Baker LD, Gleason CE, Dowling M, Barnet JH, Johnson S, Carlsson C, Craft S, Asthana S. Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. J Alzheimers Dis 2011, 26(3):495-505. 3302351, 21694454.
49. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Jama 2003, 289(20):2651-2662. 10.1001/jama.289.20.2651, 12771112.
50. Graham AJ, Martin-Ruiz CM, Teaktong T, Ray MA, Court JA. Human brain nicotinic receptors, their distribution and participation in neuropsychiatric disorders. Curr Drug Targets CNS Neurol Disord 2002, 1(4):387-397. 10.2174/1568007023339283, 12769611.
51. Rangani RJ, Upadhya MA, Nakhate KT, Kokare DM, Subhedar NK. Nicotine evoked improvement in learning and memory is mediated through NPY Y1 receptors in rat model of Alzheimer's disease. Peptides 2012, 33(2):317-328. 10.1016/j.peptides.2012.01.004, 22266216.
52. Court JA, Johnson M, Religa D, Keverne J, Kalaria R, Jaros E, McKeith IG, Perry R, Naslund J, Perry EK. Attenuation of Abeta deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking. Neuropathol Appl Neurobiol 2005, 31(5):522-535. 10.1111/j.1365-2990.2005.00674.x, 16150123.
53. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res 2005, 38(3):145-152. 10.1111/j.1600-079X.2004.00196.x, 15725334.
54. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DL, Reiter RJ, Efthimiopoulos S, Robakis NK. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997, 17(5):1683-1690.
55. Rosales-Corral SA, Lopez-Armas G, Cruz-Ramos J, Melnikov VG, Tan DX, Manchester LC, Munoz R, Reiter RJ. Alterations in Lipid Levels of Mitochondrial Membranes Induced by Amyloid-β: A Protective Role of Melatonin. Int J Alzheimers Dis 2012, 2012:459806. 3362052, 22666620.
56. Wang XC, Zhang J, Yu X, Han L, Zhou ZT, Zhang Y, Wang JZ. Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat. Sheng Li Xue Bao 2005, 57(1):7-12.
57. Chen KS, Nishimura MC, Armanini MP, Crowley C, Spencer SD, Phillips HS. Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J Neurosci 1997, 17(19):7288-7296.
58. Tuszynski MH, Thal L, Pay M, Salmon DP, Bakay HS UR, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005, 11(5):551-555. 10.1038/nm1239, 15852017.
59. Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 2004, 62(2):275-280. 10.1212/01.WNL.0000103860.75218.A5, 14745067.
60. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N, Frautschy SA, Cole GM. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005, 25(12):3032-3040. 10.1523/JNEUROSCI.4225-04.2005, 15788759.
61. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006, 63(10):1402-1408. 10.1001/archneur.63.10.1402, 17030655.
62. Rosenberg RN. Translational research on the way to effective therapy for Alzheimer disease. Arch Gen Psychiatry 2005, 62(11):1186-1192. 10.1001/archpsyc.62.11.1186, 1479851, 16275806.
63. Wang T, Wang CY, Shan ZY, Teng WP, Wang ZY. Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AβPP/PS1 transgenic mouse brain. J Alzheimers Dis 2012, 29(3):549-559.
64. Huang TC, Lu KT, Wo YY, Wu YJ, Yang YL. Resveratrol Protects Rats from Abeta-induced Neurotoxicity by the Reduction of iNOS Expression and Lipid Peroxidation. PLoS One 2011, 6(12):e29102. 10.1371/journal.pone.0029102, 3248406, 22220203.
65. Granzotto A, Zatta P. Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Abeta and Abeta-metal complexes toxicity. PLoS One 2011, 6(6):e21565. 10.1371/journal.pone.0021565, 3124535, 21738712.
66. Shan T, Wang Y, Wu T, Liu C, Guo J, Zhang Y, Liu J, Xu Z. Porcine sirtuin 1 gene clone, expression pattern, and regulation by resveratrol. J Anim Sci 2009, 87(3):895-904.